Zenas Biopharma
Zenas BioPharma Inc is a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative immunological and inflammatory therapeutics for patients suffering from severe autoimmune diseases, prominently featuring its lead product candidate obexelimab (a bifunctional monoclonal antibody targeting CD19). The company conducts advanced clinical trials evaluating targeted biological therapies designed to modulate immune system activity and treat serious autoimmune disorders. Its core business operations encompass biopharmaceutical immunology research, clinical trial execution, biologic drug formulation, and commercial pharmaceutical strategy. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its ongoing operational activities through venture capital financing and public equity offerings. Zenas BioPharma holds a leading market position in targeted immunology therapeutics. The company is headquartered in Waltham, Massachusetts, United States, and its common stock trades on the Nasdaq Global Select Market.
2 of the funds FundTelligence covers report a position in Zenas Biopharma.
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Zenas Biopharma
- Nordea Global Social Empowerment — Nordea Funds · 1.04 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.12 % (full portfolio disclosed, October 2026)